Royalty Pharma Plc Share Price (NASDAQ: RPRX)

$35.97

▲

0.35

(0.98%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Royalty Pharma Plc Stock chart to analyse performance

Royalty Pharma Plc stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$35.57
Today's High:$35.97
$35.97
1.11%
Downside
Day's Volatility :1.11%
Upside
0.0%
52 Weeks Low:$24.05
52 Weeks High:$38.00
$35.97
33.14%
Downside
52 Weeks Volatility :36.71%
Upside
5.34%

Royalty Pharma Plc Stock Returns

Period	Royalty Pharma Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	8.18%	3.6%	0.0%
6 Months	6.26%	-7.7%	0.0%
1 Year	24.58%	-12.6%	0.0%
3 Years	-14.48%	8.4%	-3.0%

Royalty Pharma Plc Key Stats

Check Royalty Pharma Plc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$35.62
Open	$35.61
Today's High	$35.97
Today's Low	$35.57
Market Capitalization	$21.0B
Today's Volume	$3.0M
52 Week High	$38.0
52 Week Low	$24.05
Revenue TTM	$2.3B
EBITDA	$1.5B
Earnings Per Share (EPS)	$2.29
PE Ratio	15.71
Dividend Yield	2.41%
Profit Margin	44.28%
Quarterly Earnings Growth YOY	-0.69%
Return On Equity TTM	17.29%

Stock Returns calculator for Royalty Pharma Plc Stock including INR - Dollar returns

The Royalty Pharma Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Royalty Pharma Plc investment value today

Current value as on today

₹1,29,834

Returns

₹29,834

(+29.83%)

Returns from Royalty Pharma Plc Stock

₹24,550 (+24.55%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Royalty Pharma Plc Stock

-29%

Period: Aug 1, 2025 to Aug 31, 2025. Change in 30 Days versus previous period

Search interest for Royalty Pharma Plc Stock from India on INDmoney has decreased by -29% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Royalty Pharma Plc

Name
Holdings %
Name
Holdings %
Morgan Stanley - Brokerage Accounts
9.49%
FMR Inc
9.12%
Vanguard Group Inc
8.42%
BlackRock Inc
5.68%
Capital Research & Mgmt Co - Division 3
5.06%
Baillie Gifford & Co Limited.
4.17%

Analyst Recommendation on Royalty Pharma Plc Stock

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Royalty Pharma Plc(by analysts ranked 0 to 5 stars)

Royalty Pharma Plc Share Price Target

What analysts predicted

Upside of 20.31%

Target:

$43.27

Current:

$35.97

Royalty Pharma Plc share price target is $43.27, a slight Upside of 20.31% compared to current price of $35.97 as per analysts' prediction.

Royalty Pharma Plc Stock Insights

Price Movement
In the last 1 month, RPRX stock has moved down by -3.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 568.24M → 578.66M (in $), with an average increase of 1.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 238.34M → 30.17M (in $), with an average decrease of 87.3% per quarter
RPRX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 46.0%
RPRX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.3% return, outperforming this stock by 125.6%
Price to Sales
ForRPRX every $1 of sales, investors are willing to pay $6.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Royalty Pharma Plc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$1.8B	↑ 1.08%
Net Income	$2.3B	↑ 70.46%
Net Profit Margin	129.45%	↑ 52.69%

	FY20	Y/Y Change
Revenue	$2.1B	↑ 16.96%
Net Income	$495.2M	↓ 78.91%
Net Profit Margin	23.34%	↓ 106.11%

	FY21	Y/Y Change
Revenue	$2.3B	↑ 7.89%
Net Income	$478.8M	↓ 3.32%
Net Profit Margin	20.91%	↓ 2.43%

	FY22	Y/Y Change
Revenue	$2.2B	↓ 2.28%
Net Income	$42.8M	↓ 91.05%
Net Profit Margin	1.91%	↓ 19.0%

	FY23	Y/Y Change
Revenue	$2.4B	↑ 5.24%
Net Income	$1.1B	↑ 2549.5%
Net Profit Margin	48.2%	↑ 46.29%

	FY24	Y/Y Change
Revenue	$2.3B	↓ 3.85%
Net Income	$859.0M	↓ 24.31%
Net Profit Margin	37.94%	↓ 10.26%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$568.0M	↓ 4.7%
Net Income	$4.8M	↓ 99.03%
Net Profit Margin	0.84%	↓ 82.1%

	Q2 FY24	Q/Q Change
Revenue	$537.3M	↓ 5.41%
Net Income	$102.0M	↑ 2034.87%
Net Profit Margin	18.99%	↑ 18.15%

	Q3 FY24	Q/Q Change
Revenue	$564.7M	↑ 5.1%
Net Income	$544.0M	↑ 433.3%
Net Profit Margin	96.33%	↑ 77.34%

	Q4 FY24	Q/Q Change
Revenue	$594.0M	↑ 5.19%
Net Income	$208.0M	↓ 61.76%
Net Profit Margin	35.02%	↓ 61.31%

	Q1 FY25	Q/Q Change
Revenue	$568.2M	↓ 4.34%
Net Income	$238.3M	↑ 14.59%
Net Profit Margin	41.94%	↑ 6.92%

	Q2 FY25	Q/Q Change
Revenue	$578.7M	↑ 1.83%
Net Income	$30.2M	↓ 87.34%
Net Profit Margin	5.21%	↓ 36.73%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$794.9M	↓ 52.08%

	FY20	Y/Y Change
Profit	$2.0B	↑ 155.86%

	FY21	Y/Y Change
Profit	$2.3B	↑ 11.44%

	FY22	Y/Y Change
Profit	$2.2B	↓ 1.54%

	FY23	Y/Y Change
Profit	$1.8B	↓ 19.61%

	FY24	Y/Y Change
Profit	$2.3B	↑ 26.21%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Profit	$-15.6M	↓ 103.01%

	Q2 FY24	Q/Q Change
Profit	$531.3M	↓ 3500.76%

	Q3 FY24	Q/Q Change
Profit	$563.0M	↑ 5.98%

	Q4 FY24	Q/Q Change
Profit	$594.0M	↑ 5.5%

	Q1 FY25	Q/Q Change
Profit	$568.2M	↓ 4.34%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$1.7B	↑ 3.02%
Investing Cash Flow	$-2.2B	↓ 809.77%
Financing Cash Flow	$-1.2B	↓ 13.59%

	FY20	Y/Y Change
Operating Cash Flow	$2.0B	↑ 22.04%
Investing Cash Flow	$-2.8B	↑ 28.12%
Financing Cash Flow	$1.5B	↓ 224.79%

	FY21	Y/Y Change
Operating Cash Flow	$2.0B	↓ 0.84%
Investing Cash Flow	$-1.9B	↓ 32.22%
Financing Cash Flow	$385.1M	↓ 74.1%

	FY22	Y/Y Change
Operating Cash Flow	$2.1B	↑ 6.27%
Investing Cash Flow	$-1.0B	↓ 44.96%
Financing Cash Flow	$-944.9M	↓ 345.35%

	FY23	Y/Y Change
Operating Cash Flow	$3.0B	↑ 39.36%
Investing Cash Flow	$-2.1B	↑ 101.35%
Financing Cash Flow	$-2.1B	↑ 127.42%

	FY24	Y/Y Change
Operating Cash Flow	$2.8B	↓ 7.32%
Investing Cash Flow	$-2.7B	↑ 29.2%
Financing Cash Flow	$361.1M	↓ 116.81%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$664.6M	↓ 13.98%
Investing Cash Flow	$-86.7M	↓ 91.34%
Financing Cash Flow	$-212.0M	↓ 8.58%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$658.2M	↓ 0.97%
Investing Cash Flow	$-893.2M	↑ 930.79%
Financing Cash Flow	$1.2B	↓ 645.58%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$703.6M	↑ 6.9%
Investing Cash Flow	$-1.2B	↑ 33.53%
Financing Cash Flow	$-325.5M	↓ 128.14%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$742.5M	↑ 5.53%
Investing Cash Flow	$-505.6M	↓ 57.61%
Financing Cash Flow	$-258.0M	↓ 20.75%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$596.1M	↓ 19.72%
Investing Cash Flow	$503.9M	↓ 199.67%
Financing Cash Flow	$-941.3M	↑ 264.9%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$427.0M	↓ 28.37%
Investing Cash Flow	$-370.1M	↓ 173.45%
Financing Cash Flow	$-512.6M	↓ 45.54%

Royalty Pharma Plc Technicals Summary

Sell

Neutral

Buy

Royalty Pharma Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Royalty Pharma Plc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Royalty Pharma Plc	-5.04%	6.26%	24.58%	-14.48%	-13.82%
Regeneron Pharmaceuticals, Inc.	1.6%	-15.21%	-50.32%	0.01%	-4.83%
Beone Medicines Ltd	0.71%	24.65%	62.57%	83.4%	30.27%
Vertex Pharmaceuticals Incorporated	-17.2%	-19.1%	-17.8%	39.13%	38.71%
Alnylam Pharmaceuticals, Inc.	6.42%	83.35%	75.94%	117.33%	241.73%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Royalty Pharma Plc	15.55	15.55	3.14	4.48	0.17	0.06	0.02	14.68
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Royalty Pharma Plc	Buy	$20.8B	-13.82%	15.55	44.28%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-4.83%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	30.27%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	38.71%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	241.73%	NA	-12.96%

Royalty Pharma Plc Dividend announcements

Royalty Pharma Plc Dividends September, 2025
In the quarter ending September,2025. Royalty Pharma Plc has declared dividend of $0.22

About Royalty Pharma Plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Organization	Royalty Pharma Plc
Employees	0
CEO	Mr. Pablo Gerardo Legorreta
Industry	Health Technology

Key Management of Royalty Pharma Plc

Name	Title
Mr. Pablo Gerardo Legorreta	Founder, Chairman of the Board & CEO
Mr. Terrance P. Coyne	Executive VP & CFO
Mr. George Wingate Lloyd	Executive VP of Investments & Chief Legal Officer
Mr. Christopher Hite	Vice Chairman & Executive VP
Dr. Marshall Jonathan Urist M.D., Ph.D.	Executive Vice President of Research & Investments
Mr. Arthur Richard McGivern J.D.	Executive Vice President of Investments & General Counsel
Mr. Ashwin Pai M.D.	Executive Vice President of Investments
Mr. Eric Cornelius Schneider	Senior VP & Chief Technology Officer
Dr. James Folmar Reddoch Ph.D.	Executive VP of Investments & Chief Scientific Officer
Mr. George Grofik C.F.A., CPA	Senior VP and Head of Investor Relations & Communications

Important FAQs about investing in RPRX Stock from India :

What is Royalty Pharma Plc share price today?

Royalty Pharma Plc share price today is $35.97 as on August 30, 2025 at 1:29 am IST at the close of the market. Royalty Pharma Plc share today touched a day high of $35.97 and a low of $35.57.

What is the 52 week high and 52 week low for Royalty Pharma Plc share?

Royalty Pharma Plc share touched a 52 week high of $38.00 and a 52 week low of $24.05. Royalty Pharma Plc stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $35.97, lower by 5.34% versus the 52 week high.

How to invest in Royalty Pharma Plc Stock (RPRX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Royalty Pharma Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Royalty Pharma Plc Shares that will get you 0.0417 shares as per Royalty Pharma Plc share price of $35.97 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Royalty Pharma Plc Stock (RPRX) from India?

Indian investors can start investing in Royalty Pharma Plc (RPRX) shares with as little as ₹88.286 or $1 (as of September 01, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Royalty Pharma Plc stock (as per the Rupee-Dollar exchange rate as on September 01, 2025). Based on Royalty Pharma Plc share’s latest price of $35.97 as on August 30, 2025 at 1:29 am IST, you will get 0.2780 shares of Royalty Pharma Plc. Learn more about fractional shares .

What are the returns that Royalty Pharma Plc has given to Indian investors in the last 5 years?

Royalty Pharma Plc stock has given -13.82% share price returns and 20.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?